Replies to post #4886 on BioCryst Pharmaceuticals,Inc. (BCRX)

[agribusiness72]

As we wait for Japan's approval I ran across this that I was unaware of: Article from November 2020. Means Revenue started then for Orladeyo!

https://angioedemanews.com/2020/11/09/berotralstat-available-to-eligible-patients-uk-through-early-access-program/


Berotralstat Available to Eligible Patients in UK Through Early Access Program

Berotralstat — an oral therapy by BioCryst Pharmaceuticals for preventing swelling attacks in people with hereditary angioedema (HAE) — will be available to patients, 12 and older, in the U.K. through an Early Access to Medicines Scheme (EAMS) before its potential regulatory approval.

An EAMS gives patient access to therapies not yet approved for commercial use to people with life-threatening or seriously debilitating conditions and a clear unmet medical need.